Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

 Dow Up0.80% Nasdaq Up0.97%

Orexigen Therapeutics, Inc. (OREX)

-NasdaqGS

6.04 Down 0.01(0.17%) May 17, 4:00PM EDT|After Hours : 6.05 Up 0.01 (0.17%) May 17, 7:41PM EDT

Add to Portfolio
ProfileGet Profile for:
Orexigen Therapeutics, Inc.
3344 North Torrey Pines Court
Suite 200
La Jolla, CA 92037
United States - Map
Phone: 858-875-8600
Fax: 858-875-8650
Website: http://www.orexigen.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Other
Full Time Employees:41

Business Summary 

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include Contrave, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic, which has completed Phase II clinical trials. The company has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in the United States, Canada, and Mexico. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Orexigen Therapeutics, Inc.

Corporate Governance 
Orexigen Therapeutics, Inc.’s ISS Governance QuickScore as of May 1, 2013 is 10. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 7; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Michael A. Narachi M.S., M.B.A., 54
Chief Exec. Officer, Pres and Director
1.22M2.61M
Mr. Joseph P. Hagan , 44
Acting Chief Financial Officer, Principal Accounting Officer, Chief Bus. Officer and Treasurer
599.00K570.00K
Ms. Heather D. Turner J.D., 40
Sr. VP, Gen. Counsel and Sec.
599.00K496.00K
Mr. Mark D. Booth , 53
Chief Commercial Officer
478.00K413.00K
Mr. Preston Klassen M.D., M.H.S., 44
Head of Global Contrave Program and Sr. VP of Product Devel.
610.00K0.00
Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders